Topical corticosteroids: guideline recommendation, potency selection, and efficacy ranges by potency class
Topical corticosteroids: local adverse effects, tachyphylaxis, and duration limits
Topical vitamin D analogues and corticosteroid combinations: guideline recommendations and adverse effects
“The long-term use of topical vitamin D analogues (up to 52 weeks), including calcipotriene/calcipotriene, calcitriol, tacalcitol, and maxacalcitol, is recommended for the treatment of mild to moderate psoriasis” (opens the source at this quote in a new tab)
“Use of combination products with calcipotriol and corticosteroids is recommended for the treatment of psoriasis” (opens the source at this quote in a new tab)
“Other local adverse effects can affect up to 35% of patients and include burning, pruritus, edema, peeling, dryness, and erythema.” (opens the source at this quote in a new tab)
“When using calcipotriene, applications of more than 100 g/wk should be avoided to minimize this risk” (opens the source at this quote in a new tab)
Topical agents added to systemic therapy in moderate to severe psoriasis: guideline recommendations
Topical agents alone among treated patients with moderate or severe psoriasis
Guideline evidence base for topical and UV therapy statements
Joint AAD-NPF guideline on topical therapy: scope and National Psoriasis Foundation collaboration